CURIS INC
10-K
March 24, 2026
Key Highlights
- Advancing emavusertib through clinical trials for AML and MDS blood cancers.
- Steady royalty income stream from the skin cancer drug Erivedge.
- Active pursuit of development partnerships to offset research costs.
Read Analysis
π€ AI Generated